Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 45
Switching to Tirzepatide: Liver Fibrosis
A Japanese study found switching from other GLP-1 drugs to tirzepatide reduced FIB-4 liver fibrosis scores in high-risk patients.
Avexitide: the GLP-1 drug that blocks it
Avexitide, Amylyx's investigational GLP-1 receptor blocker, cut severe post-bariatric hypoglycemia events by 55 percent in a phase 3 trial.
CagriSema meta-analysis: what it found
Seven pooled CagriSema trials show more weight loss than semaglutide or cagrilintide alone. The combination is still unapproved, and pooled data has limits.
ENV-308: a pill built to mimic exercise
Enveda's ENV-308 mimics an exercise-linked metabolite and aims to preserve muscle after GLP-1 weight loss, but its Phase 1 trial tested only safety.
GLP-1 Drugs and Ankle Osteoarthritis Care
A 2026 cohort study ties GLP-1 receptor agonist use to fewer ankle injections and replacements, but more arthroscopy in diabetes.
GLP-1 drugs and ankle OA: new cohort data
A Johns Hopkins cohort study found obese GLP-1 users had lower rates of ankle injection and arthroplasty. Diabetic users showed higher arthroscopy rates.
Hunger pain: semaglutide in schizophrenia
A qualitative study asked people with schizophrenia how semaglutide changed the hunger antipsychotics can cause.
Semaglutide lowers hsCRP in SELECT
A Circulation analysis of SELECT finds semaglutide 2.4 mg reduces hsCRP in adults with prior heart attack or stroke. What it means, and what it doesn't.
Sleep and mood after starting GLP-1 drugs
A new observational study links tirzepatide and semaglutide to improved sleep and depression scores at three months, with caveats.
Doctor suspended over Ozempic to partner
A GMC tribunal suspended a UK doctor for prescribing Ozempic and Wegovy, both semaglutide, to her partner without disclosure.
Experts Issue GLP-1 Guidance for NET Care
A new expert consensus statement sets ground rules for using GLP-1 drugs like tirzepatide in neuroendocrine tumor patients.
Can incretins ease psoriasis inflammation?
A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.